LATEST NEWS
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
… The recent approval by the Food and Drug Administration (FDA) of ponatinib (ICLUSIG®) in…
VIDEO highlights from @montypal 2024 Annual Oncology and Research Symposium https://oncologytube.com/tag/moasc-2024-oncology-summit/ featuring presentations from @KarenReckampMD @jtmoyers @Dr_RShatsky @arafflemd Heinz-Josef Lenz @akhtari_mojtaba @DrLizBrem @UCIrvineHealth @CancerCenter @CityofHopeCME…
Check out the incredible young investigators from @cityofhope who presented their work at #MOASC24! A huge thanks to @MOASC_Office, our state society, & @oncologytube for offering them an opportunity to shine! @SalvadorjcMD @AlexisLevee @NazliDizman @NickSalgia…
Oncology Conference Videos
Oncology News
AsCas12a Gene Editing of HBG1/2Promoters with EDIT-301 Results [ASH 2023]
Rabi Hanna, MD, from the Department of Pediatric Hematology Oncology and BMT at Cleveland Clinic…
By: Melinda Telli, MD, Date: 12/9/2023 At the SABCS 2023 conference, we had the privilege…
Al-Ola Abdallah, MD, Associate Professor of Medicine at The University of Kansas, conducted a study…
Allen Wilbanks finds himself at SABCS 2023, where he engages in a discussion with Dr.…
Brexucabtagene Autoleucel Adult B-Cell ALL Real-World Outcomes [ASH 2023]
Evandro Bezerra, MD, hematologist and assistant professor at The Ohio State University Wexner Medical Center,…
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews]
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews…
At ASH 2023, Katherine Broome, MD, a medical doctor and medical oncologist at the Georgetown…
By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical…
BTK Inhibitor Use and Social Determinants in CLL / SLL [ASH 2023]
David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member…
Sonrotoclax + Zanubrutinib Well Tolerated Deep Responses TN-CLL/SLL [ASH 2023]
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology,…
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews]
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews…
Sumanta (Monty) Kumar Pal, MD – Highlights and Insights from MOASC 2024 Summit: Pioneering Oncology Research and Celebrating Young Investigators
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set…